- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
- 10-K Annual report
- 10.16 EX-10.16
- 10.17 EX-10.17
- 10.18 EX-10.18
- 10.19 EX-10.19
- 10.20 EX-10.20
- 10.21 EX-10.21
- 10.22 EX-10.22
- 10.23 EX-10.23
- 10.30 EX-10.30
- 10.32 EX-10.32
- 10.33 EX-10.33
- 10.34 EX-10.34
- 10.37 EX-10.37
- 10.38 EX-10.38
- 21.1 EX-21.1
- 23.1 EX-23.1
- 31.1 EX-31.1
- 31.2 EX-31.2
- 32.1 EX-32.1
- 32.2 EX-32.2
- 97 EX-97
- Download Excel data file
- View Excel data file
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statement (Form S-3 No. 333-259966) of Immunome, Inc.,
(2) Registration Statement (Form S-8 No. 333-254731) pertaining to the 2008 Amended and Restated Equity Incentive Plan, the 2018 Amended and Restated Equity Incentive Plan, the 2020 Equity Incentive Plan, and the 2020 Employee Stock Purchase Plan of Immunome, Inc.,
(3) Registration Statement (Form S-8 No. 333-270598) pertaining to the 2020 Equity Incentive Plan and the 2020 Employee Stock Purchase Plan of Immunome, Inc.,
(4) Registration Statement (Form S-8 POS No. 333-273792) pertaining to the Morphimmune 2020 Equity Incentive Plan, including Options Assumed by Immunome, Inc. Originally Granted Thereunder,
(5) Registration Statement (Form S-3 No. 333-275598) of Immunome, Inc.,
(6) Registration Statement (Form S-8 No. 333-276839) pertaining to the 2020 Equity Incentive Plan, the 2020 Employee Stock Purchase Plan, and the Individual Nonqualified Stock Option Award (Inducement Grant) of Immunome, Inc., and
(7) Registration Statement (Form S-3 No. 333-277036) of Immunome, Inc.;
(8) ) Registration Statement (Form S-1 No. 333-256018) of Immunome, Inc.
of our report dated March 28, 2024, with respect to the consolidated financial statements of Immunome, Inc. included in this Annual Report (Form 10-K) of Immunome, Inc. for the year ended December 31, 2023.
/s/ Ernst & Young LLP
Philadelphia, Pennsylvania
March 28, 2024